BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38000668)

  • 1. Performance characteristics of Allele-Specific PCR (ASPCR) in detecting drug resistance mutations among non-B HIV-1 Variants.
    Adawaye C; Fokam J; Kamangu EN; Ngwese DTA; Susin F; Moussa AM; Hig-Zounet B; Mad-Toingué J; Tidjani A; Vaira D; Moutschen M
    J Virol Methods; 2024 Jan; 323():114856. PubMed ID: 38000668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of 454 Ultra-Deep Sequencing and Allele-Specific Real-Time PCR with Regard to the Detection of Emerging Drug-Resistant Minor HIV-1 Variants after Antiretroviral Prophylaxis for Vertical Transmission.
    Hauser A; Kuecherer C; Kunz A; Dabrowski PW; Radonić A; Nitsche A; Theuring S; Bannert N; Sewangi J; Mbezi P; Dugange F; Harms G; Meixenberger K
    PLoS One; 2015; 10(10):e0140809. PubMed ID: 26469189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allele-specific real-time PCR testing for minor HIV-1 drug resistance mutations: assay preparation and application to reveal dynamic of mutations in vivo.
    Guo DX; Li HP; Li L; Zhuang DM; Jiao LY; Wang Z; Bao ZY; Liu SY; Liu YJ; Li JY
    Chin Med J (Engl); 2010 Dec; 123(23):3389-95. PubMed ID: 22166519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection and quantification of minor human immunodeficiency virus type 1 variants harboring K103N and Y181C resistance mutations in subtype A and D isolates by allele-specific real-time PCR.
    Hauser A; Mugenyi K; Kabasinguzi R; Bluethgen K; Kuecherer C; Harms G; Kunz A
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2965-73. PubMed ID: 19433556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal Detection and Persistence of Minority Drug-Resistant Populations and Their Effect on Salvage Therapy.
    Nishizawa M; Matsuda M; Hattori J; Shiino T; Matano T; Heneine W; Johnson JA; Sugiura W
    PLoS One; 2015; 10(9):e0135941. PubMed ID: 26360259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virological response, HIV-1 drug resistance mutations and genetic diversity among patients on first-line antiretroviral therapy in N'Djamena, Chad: findings from a cross-sectional study.
    Adawaye C; Fokam J; Kamangu E; Alio HM; Chahad AM; Susin F; Moussa AM; Bertin TH; Tidjani A; Vaira D; Moutschen M
    BMC Res Notes; 2017 Nov; 10(1):589. PubMed ID: 29126456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly-sensitive allele-specific PCR testing identifies a greater prevalence of transmitted HIV drug resistance in Japan.
    Nishizawa M; Hattori J; Shiino T; Matano T; Heneine W; Johnson JA; Sugiura W
    PLoS One; 2013; 8(12):e83150. PubMed ID: 24358257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of LigAmp and an ASPCR assay for detection and quantification of K103N-containing HIV variants.
    Church JD; Towler WI; Hoover DR; Hudelson SE; Kumwenda N; Taha TE; Eshleman JR; Eshleman SH
    AIDS Res Hum Retroviruses; 2008 Apr; 24(4):595-605. PubMed ID: 18370589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-resistance mutations number and K70R or T215Y/F substitutions predict treatment resumption during guided treatment interruptions.
    Darwich L; Esteve A; Ruiz L; Paredes R; Bellido R; Cabrera C; Romeu J; Bofill M; Clotet B; Martinez-Picado J
    AIDS Res Hum Retroviruses; 2008 May; 24(5):725-32. PubMed ID: 18462084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gag P2/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG- and non-CRF02_AG-infected patients in Yaoundé, Cameroon.
    Teto G; Tagny CT; Mbanya D; Fonsah JY; Fokam J; Nchindap E; Kenmogne L; Njamnshi AK; Kanmogne GD
    Sci Rep; 2017 Oct; 7(1):14136. PubMed ID: 29074854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV virologic response, patterns of drug resistance mutations and correlates among adolescents and young adults: A cross-sectional study in Tanzania.
    Rugemalila J; Kamori D; Kunambi P; Mizinduko M; Sabasaba A; Masoud S; Msafiri F; Mugusi S; Mutagonda R; Mlunde L; Amani D; Mboya E; Mahiti M; Ruhago G; Mushi J; Sambu V; Mgomella G; Jullu B; Maokola W; Njau P; Mutayoba B; Barabona G; Ueno T; Pembe A; Nagu T; Sunguya B; Aboud S
    PLoS One; 2023; 18(2):e0281528. PubMed ID: 36821538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmission.
    Hauser A; Sewangi J; Mbezi P; Dugange F; Lau I; Ziske J; Theuring S; Kuecherer C; Harms G; Kunz A
    PLoS One; 2012; 7(2):e32055. PubMed ID: 22384138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern South Africa.
    Etta EM; Mavhandu L; Manhaeve C; McGonigle K; Jackson P; Rekosh D; Hammarskjold ML; Bessong PO; Tebit DM
    AIDS Res Ther; 2017 Jul; 14(1):36. PubMed ID: 28750647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults.
    Namakoola I; Kasamba I; Mayanja BN; Kazooba P; Lutaakome J; Lyagoba F; Kapaata AA; Kaleebu P; Munderi P;
    BMC Res Notes; 2016 Dec; 9(1):515. PubMed ID: 28010730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Added Value of Next Generation over Sanger Sequencing in Kenyan Youth with Extensive HIV-1 Drug Resistance.
    Novitsky V; Nyandiko W; Vreeman R; DeLong AK; Manne A; Scanlon M; Ngeresa A; Aluoch J; Sang F; Ashimosi C; Jepkemboi E; Orido M; Hogan JW; Kantor R;
    Microbiol Spectr; 2022 Dec; 10(6):e0345422. PubMed ID: 36445146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of two HIV-1 infectors during initial antiretroviral treatment, and the emergence of phenotypic resistance in reverse transcriptase-associated mutation patterns.
    Guo W; Han J; Zhuang D; Liu S; Liu Y; Li L; Li H; Bao Z; Wang F; Li J
    Virol J; 2015 Nov; 12():187. PubMed ID: 26578099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-retroviral drug resistance-associated mutations among non-subtype B HIV-1-infected Kenyan children with treatment failure.
    Lwembe R; Ochieng W; Panikulam A; Mongoina CO; Palakudy T; Koizumi Y; Kageyama S; Yamamoto N; Shioda T; Musoke R; Owens M; Songok EM; Okoth FA; Ichimura H
    J Med Virol; 2007 Jul; 79(7):865-72. PubMed ID: 17516531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multimethod Longitudinal HIV Drug Resistance Analysis in Antiretroviral-Therapy-Naive Patients.
    Nanfack AJ; Redd AD; Bimela JS; Ncham G; Achem E; Banin AN; Kirkpatrick AR; Porcella SF; Agyingi LA; Meli J; Colizzi V; Nádas A; Gorny MK; Nyambi PN; Quinn TC; Duerr R
    J Clin Microbiol; 2017 Sep; 55(9):2785-2800. PubMed ID: 28659324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations.
    Paredes R; Marconi VC; Campbell TB; Kuritzkes DR
    J Virol Methods; 2007 Dec; 146(1-2):136-46. PubMed ID: 17662474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.
    Boender TS; Kityo CM; Boerma RS; Hamers RL; Ondoa P; Wellington M; Siwale M; Nankya I; Kaudha E; Akanmu AS; Botes ME; Steegen K; Calis JC; Rinke de Wit TF; Sigaloff KC
    J Antimicrob Chemother; 2016 Oct; 71(10):2918-27. PubMed ID: 27342546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.